Diabetes and obesity care were a key growth driver, however the company lowered its expectations for growth, citing ...
Pfizer and Novo Nordisk are in a heated legal and bidding war over Metsera, an obesity drug developer. Novo's $10 billion bid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results